These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34590739)

  • 1. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
    Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
    Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone.
    Xu B; Chen Y; Chen X; Gan L; Zhang Y; Feng J; Yu L
    Front Oncol; 2021; 11():730638. PubMed ID: 34722271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score.
    Markin PA; Brito A; Moskaleva N; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; La Frano MR; Appolonova SA
    Metabolomics; 2020 Jun; 16(7):74. PubMed ID: 32556743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia.
    Markin PA; Brito A; Moskaleva N; Fodor M; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; Lyundup AV; Appolonova SA
    Lab Med; 2020 Nov; 51(6):566-573. PubMed ID: 32161964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study.
    Struck-Lewicka W; Kordalewska M; Bujak R; Yumba Mpanga A; Markuszewski M; Jacyna J; Matuszewski M; Kaliszan R; Markuszewski MJ
    J Pharm Biomed Anal; 2015; 111():351-61. PubMed ID: 25684700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GC-MS-based metabolomics reveals new biomarkers to assist the differentiation of prostate cancer and benign prostatic hyperplasia.
    Wang W; He Z; Kong Y; Liu Z; Gong L
    Clin Chim Acta; 2021 Aug; 519():10-17. PubMed ID: 33831421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
    PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
    Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
    Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the plasma level of long non-coding RNA PCAT1 in prostatic hyperplasia and newly diagnosed prostate cancer patients.
    Rezatabar S; Moudi E; Sadeghi F; Khafri S; Kopi TA; Parsian H
    J Gene Med; 2020 Oct; 22(10):e3239. PubMed ID: 32529802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
    Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
    Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia.
    Giskeødegård GF; Hansen AF; Bertilsson H; Gonzalez SV; Kristiansen KA; Bruheim P; Mjøs SA; Angelsen A; Bathen TF; Tessem MB
    Br J Cancer; 2015 Dec; 113(12):1712-9. PubMed ID: 26633561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.
    Wu T; Kasper S; Wong RM; Bracken B
    Clin Genitourin Cancer; 2020 Apr; 18(2):e174-e179. PubMed ID: 31899150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia.
    Fu S; Zhang X; Niu Y; Wang RT
    Asian Pac J Cancer Prev; 2018 Mar; 19(3):699-702. PubMed ID: 29580043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New findings on urinary prostate cancer metabolome through combined GC-MS and
    Lima AR; Pinto J; Barros-Silva D; Jerónimo C; Henrique R; Bastos ML; Carvalho M; Guedes Pinho P
    Metabolomics; 2020 Jun; 16(6):70. PubMed ID: 32495062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C; Lein M; Jung K; Schnorr D; Loening SA
    Cancer; 1997 Jan; 79(1):104-9. PubMed ID: 8988733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer.
    He J; Han Z; Luo W; Shen J; Xie F; Liao L; Zou G; Luo X; Guo Z; Li Y; Li J; Chen H
    Front Immunol; 2022; 13():998447. PubMed ID: 36685547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of prostatic disease and prostatic manipulations on the concentration of prostate-specific antigen.
    Walz PH; Schoppmann T; Büscher C; Ennen J; Schriewer H
    Eur Urol; 1992; 22(1):20-6. PubMed ID: 1385141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GC-MS-based untargeted metabolomics of plasma and urine to evaluate metabolic changes in prostate cancer.
    Struck-Lewicka W; Wawrzyniak R; Artymowicz M; Kordalewska M; Markuszewski M; Matuszewski M; Gutknecht P; Siebert J; Markuszewski MJ
    J Breath Res; 2020 Sep; 14(4):047103. PubMed ID: 32969349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer.
    Li C; Zang T; Wrobel K; Huang JT; Nabi G
    Anal Bioanal Chem; 2015 May; 407(12):3393-404. PubMed ID: 25724369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.